44 million people of more than 50 years old in the US are suffering from<unk> , more than half of over 50 years people. Remaining the current conditions and utilities, it is estimated that more than 61 million people in 2020 would be suffering from<unk> . Women constitute 80% of the osteoporotic population. Parathormone (PTH) analogues (teriparatide and abaloparatide) have more prices and quality-adjusted life years (QALYs) in contrast with zoledronate. Teriparatide and abaloparatide are $43,440 and $22,061 more costly than zoledronate. In Europe the whole cost of medical therapies for<unk>  in 2010 was €37 billion, in which 66% was for acute fractures management, 29% was for long-term fracture outcome management, and 5% was for medical prevention. On the other hand, the holistic burden of<unk>  in Europe assumed to be the loss of 1,180,000 life years (QALY), most of them because of prior osteoporotic fractures. Regarding that one QALY is equal value of 2xGDP, it is assumed that the total burden of<unk>  become €60.4 billion, in 2010. Surprisingly, the QALY number will rise from 1.2 million in 2010 to about 1.4 million years in 2025, with 20% increase.
Osteoporosis cost-effectiveness of therapy
Hirsutism cost-effectiveness of therapy
Menopause cost-effectiveness of therapy
Osteoporosis future or investigational therapies
Hearing impairment cost-effectiveness of therapy
Minimal change disease cost-effectiveness of therapy
Anhedonia cost-effectiveness of therapy
Osteosarcoma cost-effectiveness of therapy